Integrum AB appoints Martin Hillsten as new CEO

Investing.com -- Integrum AB (Nasdaq First North Growth Market:INTEG B) announced today the appointment of Martin Hillsten as the new Chief Executive Officer (CEO), effective immediately. Hillsten replaces Scott Flora, the acting CEO, who will now advise on US marketing activities and maintain his position on the company’s Board of Directors.

Hillsten, who was born in 1978, brings a wealth of experience to the role. He previously served as the CEO of Integration Diagnostics and has a long history in the sales and marketing of advanced medical devices in the US and globally. Hillsten holds a Bachelor of Business Administration from the University of Lincoln, UK, and has spent two decades in the life sciences industry, focusing on implant products and diagnostic imaging.

In his prior role at Integration Diagnostics, a firm that develops, manufactures, and markets products to assess the stability of an implant and its ability to integrate with bone tissue, Hillsten oversaw a business where 70% of revenues were derived from the US market. He has also held senior sales and marketing positions at Bracco Diagnostics and currently owns 42,000 shares in Integrum.

Integrum is in the process of a strategic shift to enhance market penetration of its OPRA® Implant System, with a particular focus on the US and selected European countries. The strategy involves a focus on selected Centers of Excellence, a bolstered aftermarket approach, and an operational optimization expected to yield up to SEK 20 million in annual cost savings once fully implemented in early 2026.

Beng Sjöholm, Chairman of the Board at Integrum, praised the work of acting CEO Scott Flora in establishing an efficient structure to boost market penetration of the OPRA® Implant System. He expressed confidence in Hillsten’s ability to leverage the strategic shift initiated by the Board earlier this year, citing his extensive experience in sales and marketing of advanced medical devices and dedication to creating value for patients and shareholders.

Scott Flora will continue to support the implementation of Integrum’s marketing strategy in the US in an advisory capacity and will remain on the company’s Board of Directors.

Martin Hillsten, the incoming CEO of Integrum, expressed his admiration for the company’s revolutionary implant system and optimism about the strategic shift being implemented. He sees potential for significant shareholder value creation by offering the OPRA® Implant System to enhance the mobility of an increasing number of amputees. He also committed to ensuring sales growth while continuing the implementation of cost efficiencies aimed at significantly improving operating margins.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.